A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

324

Participants

Timeline

Start Date

February 12, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

December 31, 2027

Conditions
Developmental and Epileptic Encephalopathy
Interventions
DRUG

LP352

LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube.

Trial Locations (33)

2031

Site Number - AUS07, Randwick

Site Number - AUS08, Randwick

3004

Site Number - AUS03, Melbourne

3084

Site Number - AUS02, Heidelberg

4006

Site Number - AUS04, Herston

4101

Site Number - AUS05, South Brisbane

10016

Site Number - USA32, New York

20817

Site Number - USA07, Bethesda

29425

Site Number - USA22, Charleston

30329

Site Number - USA09, Atlanta

32561

Site Number - USA02, Gulf Breeze

32806

Site Number - USA05, Orlando

33155

Site Number - USA37, Miami

33609

Site Number - USA11, Tampa

38103

Site Number - USA34, Memphis

43205

Site Number - USA35, Columbus

44195

Site Number - USA39, Cleveland

45229

Site Number - USA14, Cincinnati

55905

Site Number - USA15, Rochester

60611

Site Number - USA38, Chicago

72202

Site Number - USA19, Little Rock

76104

Site Number - USA31, Fort Worth

77030

Site Number - USA25, Houston

80045

Site Number - USA17, Aurora

90027

Site Number - USA26, Los Angeles

90095

Site Number - USA18, Los Angeles

92037

Site Number - USA29, La Jolla

94304

Site Number - USA24, Palo Alto

94904

Site Number - USA28, San Francisco

97239

Site Number - USA33, Portland

98405

Site Number - USA03, Tacoma

07039

Site Number - USA10, Livingston

07961

Site Number - USA36, Morristown

Sponsors
All Listed Sponsors
lead

Longboard Pharmaceuticals

INDUSTRY